GlassScriptPhysician profile
Richard J Michael
NPI 1861496671
$2,923.27
in general payments reported to CMS, 2019-2025
29 companies · $674 in 2025
The $674 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $201 · 2020: $328 · 2021: $487 · 2022: $298 · 2023: $221 · 2024: $715 · 2025: $674.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,610.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,610.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $939.09 | 2019-2025 | Evenity, Repatha, Otezla |
| Novo Nordisk INC | $229.01 | 2020-2024 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $219.43 | 2020-2024 | Mounjaro, Zepbound, Jardiance |
| Lundbeck LLC | $170.22 | 2023-2025 | Rexulti, Vyepti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $166.06 | 2019-2024 | Jardiance |
| Astellas Pharma US INC | $132.84 | 2019-2024 | Veozah |
| Novartis Pharmaceuticals Corporation | $100.11 | 2021-2024 | |
| Pfizer INC. | $95.52 | 2022-2025 | |
| Ardelyx, INC. | $89.78 | 2024-2025 | Ibsrela |
| Abbvie INC. | $87.83 | 2021-2025 | |
| Cleerly, INC. | $83.91 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Glaxosmithkline, LLC. | $83.64 | 2019-2023 | Shingrix, Arexvy |
| Axsome Therapeutics, INC. | $57.58 | 2025 | Auvelity |
| Antares Pharma, INC. | $55.32 | 2025 | Xyosted |
| Itamar Medical INC | $55.09 | 2022-2024 | Watchpatone |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $54.62 | 2024-2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $41.11 | 2019-2023 | Farxiga |
| Exact Sciences Corporation | $36.81 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $32.86 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.18 | 2020 | |
| Idorsia Pharmaceuticals US INC | $22.62 | 2024 | Quviviq |
| Cvrx, INC. | $22.60 | 2024 | Barostim Neo System |
| Mckesson Medical-Surgical, INC. | $21.06 | 2022 | |
| Phathom Pharmaceuticals, INC. | $20.36 | 2025 | Voquezna |
| Tolmar, INC. | $18.38 | 2025 | Jatenzo |
| Philips North America LLC | $17.69 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $17.30 | 2023 | Nuedexta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.44 | 2023 | Xifaxan |
| Allergan, INC. | $11.81 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Michael listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.